(January 8, 2020, 12:20 PM EST) -- WILMINGTON, Del. — A federal bankruptcy trustee and the U.S. Securities and Exchange Commission on Jan. 6 objected to how a proposed liquidation plan for opioid maker Insys Therapeutics Inc. treats stockholders who will be left with worthless shares of the company (In Re: Insys Therapeutics, Inc., et al., No. 19-11292, D. Del. Bkcy.)....